SLA 1.12% $4.50 silk laser australia limited

need more than the quarterly, page-23

  1. 3,775 Posts.
    Investors seem to have not done their reearch on current treatment for liver disease ie: HCV ... IMO

    Results of liver function tests qualitive/quantative data ALT AST levels in particular ... these results will determine efficacy of treatment.

    Viral load PCR quantity IU/ml of blood detectable HCV virus in patients blood stream.

    Recognised worldwide in clinical trials as leading indicators.

    Where are these results?
 
watchlist Created with Sketch. Add SLA (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.